Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Eukaryotic Gene Expression
Facteur d'impact: 2.156 Facteur d'impact sur 5 ans: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Imprimer: 1045-4403
ISSN En ligne: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2020033704
pages 323-336

Drug Resistance in Hepatitis C Virus: Future Prospects and Strategies to Combat It

Iqra Almas
Division of Molecular Virology & Molecular Diagnostics, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
Samia Afzal
Division of Molecular Virology & Molecular Diagnostics, National Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan
Hamna Imtiaz
Division of Molecular Virology & Molecular Diagnostics, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
Mahrukh Akbar Shaheen
Division of Molecular Virology & Molecular Diagnostics, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
Muhammad Daud
Division of Molecular Virology & Molecular Diagnostics, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
Anam Saghir
Division of Molecular Virology & Molecular Diagnostics, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
Iram Amin
Centre of Applied Molecular Biology (CAMB), University of the Punjab, Lahore-Pakistan; Division of Molecular Virology and Infectious Diseases, Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore-Pakistan
Muhammad Shahid
Division of Molecular Virology and Infectious Diseases, Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Thokar Niaz Baig, Lahore, Pakistan
Muhammad Idrees
Division of Molecular Virology and Infectious Diseases, Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore-Pakistan; Hazara University, Khyber Pakhtunkhwa, Pakistan

RÉSUMÉ

Induction of highly pathogenic hepatitis C virus (HCV) causes chronic hepatitis round the world. This virus is easily prone to developing resistance against antiviral drugs because of two viral polymerases that do not possess the proofreading and overlapping reading frame abilities. There is more than one explanation for how this virus builds up resistance against antiviral drug treatments. Assays are now available to detect HCV-resistant variants, based on phenotypic and genotypic assays, and next generation sequencing. But these assays are of a little value at baseline, because they are not influential enough for making therapeutic decisions in HCV patients. Moreover, HCV monitoring is now an essential part of clinical practice. Special patients, such as those with thalassemia, renal transplant due to renal failure, and the patients undergoing hemodialysis, are at higher risk for acquiring this infection. Management of HCV infection in these patient groups is complicated by multiple side effects, including flu-like symptoms, neutropenia, fever, and neuropsychiatric disorders, thus limiting the use of ribavirin and coexisting iron overload. In HCV patients suffering from depression, the treatment may be discontinued because of some defects in neurochemical pathways caused by interferon, which can enhance the level of depression in these patients. In addition, obesity has been found to be a marker of failure of HCV treatment. There will be many resistance tolerant HCV treatment options available in the near future.

RÉFÉRENCES

  1. Sockalingam S, Abbey SE. Managing depression during hepatitis C treatment. Can J Psych. 2009;54(9):614-25.

  2. Alavian S, Tabatabaei S, Bagheri LK. Epidemiology of HCV infection among thalassemia patients in eastern Mediterranean countries: A quantitative review of literature. Iran Red Crescent Med J. 2010;12(4):365-76.

  3. Alavian SM, Tabatabaei SV, Ayyub M. Outcome of combination antiviral therapy in hepatitis C virus infected patients with sickle cell disease. Saudi Med J. 2009;30(8):1107-8.

  4. Booth DR, Ahlenstiel G, George J. Pharmacogenomics of hepatitis C infections: Personalizing therapy. Genome Med. 2012;4(12):99.

  5. Alavian SM, Tabatabaei SV. Treatment outcome of chronic hepatitis C in sickle cell disease and thalassemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol. 2010;22(1):123-4.

  6. Alpers C, Bloom RD, Fabrizi F, Izopet J, Jadoul M, Lindley E, Martin P, Morales JM, Natov S, Pol S, Reddy KR, Rostaing L, Roth D, Wei L, Alter M, Lavanchy D, Meyers C, Seeff L, Eknoyan G, Lameire N, Balk E, Craig J, Earley A, Gordon C, Ioannidis J, Jadoul M, Roth D. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease: Introduction. Kidney Int. 2008;73(Suppl 109):S6-S99.

  7. Ancel D, Amiot X, Chaslin-Ferbus D, Hagege I, Garioud A, Girot R, Pol S, Grange JD. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol. 2009;21(7):726-9.

  8. Chayama K, Suzuki Y, Ikeda K, Toyota J, Karino Y, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Wenhua Hu, Ishikawa H, Hughes E, Kumada H. All-oral combination of daclatasvir plus asunaprevir in interferon ineligible naive/intolerant and nonresponder Japanese patients chronically infected with HCV genotype 1b: Results from a phase 3 trial. Hepatology. 2013;58(Suppl 1):313A.

  9. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: Epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol. 2015;28(2):221-8.

  10. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008;198(6):800-7.

  11. Batki SL, Canfield KM, Ploutz-Snyder R. Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: Effects on eligibility for hepatitis C treatment. Am J Addict. 2011;20(4):312-8.

  12. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013;110(10):3991-6.

  13. Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe IA, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, McKeating JA. Hepatitis C virus infects the endothe- lial cells of the blood-brain barrier. Gastroenterology. 2012;142(3):634-43.

  14. Matsuura K, Watanabe T, Tanaka Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J Gastroenterol Hepatol. 2014;29(2):241-9.

  15. Chevaliez S, Pawlotsky J-M. Interferons and their use in persistent viral infections. In: Krausslich HG, Barten-schlager R, editors. Antiviral strategies. Handbook of experimental pharmacology. Vol 189. New York: Springer; 2009. p. 203-41.

  16. Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology. 2012;142(6):1303-13.

  17. McGivern DR, Masaki T, Williford S, Ingravallo P, Feng Z, Lahser F, Asante-Appiah E, Neddermann P, Francesco RD, Howe AY, Lemon SM. Kinetic analyses of antiviral suppression by NS5A inhibitors reveal early and potent inhibition of viral assembly and release of infectious virus. Hepatology. 2013;58(Suppl 1):246A.

  18. Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: A meta-analysis. J Viral Hepat. 2010;17(4):236-44.

  19. Mangia A, Thompson A J, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139(3):821-7.

  20. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87.

  21. Mira JA, Lopez-Cortes LF, Barreiro P, Tural C, Torres-Tortosa M, de los Santos Gil I, Martin-Rico P, Rios-Villegas MJ, Hernandez-Burruezo JJ, Merino D, Lopez-Ruz MA, Rivero A, Munoz L, Gonzalez-Serrano M, Collado A, Madas J, Viciana P, Soriano V, Pineda JA. Efficacy of pegylated interferon plus ribavirin treatment in HIV/ hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother. 2008;62(6):1365-73.

  22. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. New Eng J Med. 2011;364(13):1207-17.

  23. Habersetzer F, Leboeuf C, Doffoel M, Baumert TF. Boceprevir and personalized medicine in hepatitis C virus infection. Pharmgenomics Pers Med. 2012;5:125-37.

  24. Halfon P, Bourliere M, Ouzan D, Maor Y, Renou C, Wartelle C, Penaranda G, Tran A, Botta D, Oules V, Castellani P, Portal I, Argiro L, Dessein A. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur J Gastroenterol Hepatol. 2011;23(10):931-5.

  25. Jacobson IM, Asselah T, Ferenci P, Foster GR, Jensen DM, Negro F, Mantry P, Wright D, Forns X, Garcia-Samaniego J, Oliveira C, Carvalho A, Forton D, Agarwal K, Arasteh K, Cooper C, Ghesquiere W, Dufour JF, Sakai Y, Tanaka Y, Stern JO, Sha N, Boecher WO, Steinmann G, Quinson AM. A randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon a-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. Hepatology. 2013;58(Suppl 1):742A.

  26. Jacobson I, Dore G, Foster G. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection for chronic HCV genotype 1 infection in treatment-naive patients: Results from QUEST-1, a phase III trial. J Hepatol. 2013;58(Suppl 2): Abstract 1425.

  27. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Tarek Al-Assi M, Subramanian GM, Di An, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-77.

  28. Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685-94.

  29. Kirst ME, Li EC, Wang CX, Dong HJ, Liu C, Fried MW, Nelson DR, Wang GP. Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients. PLoS One. 2013;8(7):e69698.

  30. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, 0rum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198-201.

  31. Karimi M, Marvasti VE, Rasekhi A, Kumar PV, Bordbar M, Moshiri A, Hasanpour P, Serajzadeh K. MRI evaluation of liver iron concentration in patients with P-thalassemia major. Hepat Mon. 2010;10(2):149-50.

  32. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34-44.

  33. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: Results from the LONESTAR-2 study. Hepatology. 2013;58(Suppl 1):1380A.

  34. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206.

  35. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16.

  36. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Arthur Y Kim AY, Yanming Xing Y, Arne Schneidewind A, Margaret A Madey MA, Jaquelyn F Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. Naturally occurring dominant resistance mutations to hepatitis C virus protease and poly-merase inhibitors in treatment-naive patients. Hepatology. 2008;48(6):1769-78.

  37. Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection. J Gastroenterol Hepatol. 2010;25(2):259-63.

  38. Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky J-M, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley RT, Seiwert S, Standring D, Stuyver L, Sullivan J, Miller V. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: Recommendations from the HCV DRAG. Gastroenterology. 2011;140(3):755-60.

  39. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol. 2013;59(2):375-82.

  40. Pawlotsky JM. The science of direct-acting antiviral and host-targeted agent therapy. Antivir Ther. 2012;17(6 Pt B):1109-17.

  41. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky J-M. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One. 2009;4(12):e8209.

  42. Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Berak H, Vierling JM, Tavel JA, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, Najera I, Lim CY, Shulman NS, Yetzer ES. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +- peginterferon alfa-2a (40KD)(P) in HCV genotype 1-infected partial and null responders: Results from the MATTERHORN study. Hepatology. 2012;56(S4):231A-2A.

  43. Habersetzer F, Leboeuf C, Doffoel M, Baumert TF. Boceprevir and personalized medicine in hepatitis C virus infection. Pharmgenomics Pers Med. 2012;5:125-37.

  44. Coppola N, Stanzione M, Messina V, Pisaturo M, De Pascalis S, Macera M, Tonziello G, Fiore M, Sagnelli C, Pasquale G, Sagnelli E. Tolerability and efficacy of anti-HBV nucleos (t) ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J Viral Hepat. 2012;19(12):890-6.

  45. Raimondo G, Saitta C. Treatment of the hepatitis B virus and hepatitis C virus co-infection: Still a challenge for the hepatologist. J Hepatol. 2008;49(5):677-9.

  46. Rockstroh J, Nelson M, Soriano V, Arasteh K, Guardiola J, Bhagani S, Mallolas J, Tural C, Puoti M, Ingiliz P, Battegay M, Jain M, Marks K, Kort J, Stern J, Vinisko R, Manero M, Dieterich D. Phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: End of treatment response (ETR). Hepatology. 2013;58.

  47. Baldick CJ, Tenney DJ, Mazzucco CE, Eggers BJ, Rose RE, Pokornowski KA, Yu CF, Colonno RJ. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology. 2008;47(5):1473-82.

  48. Halfon P, Bourliere M, Ouzan D, Maor Y, Renou C, Wartelle C, Penaranda G, Tran A, Botta D, Oules V, Castellani P, Portal I, Argiro L, Dessein A. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C genotype 1 virus. Euro J Gastroenterol Hepatol. 2011;23(10):931-5.

  49. Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont J-M, Vuagniaux G, Neyts J. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother. 2009;53(3):967-76.

  50. Smith KJ, Norris S, O'Farrelly C, O'Mara SM. Risk factors for the development of depression in patients with hepatitis C taking interferon-a. Neuropsychiatr Dis Treat. 2011;7:275-92.

  51. Slev P. Host genomics and HCV personalized medicine. Ann Clin Lab Sci. 2012;42(4):363-9.

  52. Sockalingam S, Links PS, Abbey SE. Suicide risk in hepatitis C and during interferon-alpha therapy: A review and clinical update. J Viral Hepat. 2011;18(3):153-60.

  53. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Elizee PK, Zamani F, Kafiabad SA, Gharehbaghian A, Hajibeigy B, Lankarani KB. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012;12(6):372-81.

  54. Taher AT, Musallam KM, Khalife M, Barada K. Hepatitis C antiviral response in thalassemia: What is the role of liver iron concentration? Ann Hematol. 2009;88(10):1033-4.

  55. Chow J, Liu Y, Comstock K, Brandl M, Lin F, Li F, Sarma K, Alfredson T. Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor. J Pharm Biomed Anal. 2010;53(3):710-6.

  56. Vierling J, Ralston R, Lawitz E, McCone J, Gordon S, Pound D, Davis M, Galati J, Jacobson I, Rossaro L, Anderson F, King J, Cassidy W, Bourliere M, Esteban-Mur R, Ravendhran N, Galler G, Mendez P, Brass C, Albrecht J. Long-term outcomes following combination treatment with boceprevir plus peg-intron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1). J Hepatol. 2010;52:S470-1.

  57. Vierling JM, Kwo PY, Lawitz E, McCone J, Schiff ER, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin RA, Pedicone LD, Chaudhri E, Tong X, Qiu P, Brass CA, Albrecht JK, Mendez P, Ralston R. Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir plus PEGINTRON (Peginterferon Alfa-2b)/ribavirin in patients with chronic hepatitis C, genotype 1 (G1). Hepatology. 2010;52:702A.

  58. Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martin-Carbonero L, Rodriguez-Novoa S, Santos I, Lopez-Cortes LF, Merino D, Rivero A, Soriano V. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008;13(3):429-37.

  59. Weissenborn K, Tryc AB, Heeren M, Worthmann H, Pflugrad H, Berding G, Bokemeyer M, Tillmann HL, Goldbecker A. Hepatitis C virus infection and the brain. Metab Brain Dis. 2009;24(1):197-210.

  60. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013;57(6):2135-42.

  61. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-28.


Articles with similar content:

Autoimmune Hepatitis: Factors Involved in Initiation and Methods of Diagnosis and Treatment
Critical Reviews™ in Immunology, Vol.36, 2016, issue 5
Marilina Tampoia, Franco Dammacco, Gianfranco Lauletta, Fabio Pavone, Sabino Russi, Andrea Marzullo, Domenico Sansonno
Global Epidemic of Human T-Cell Lymphotrophic Virus Type-I (HTLV-I): An Update
Journal of Long-Term Effects of Medical Implants, Vol.13, 2003, issue 2
Lisa G. Hill, Richard Edlich, Freddie M. Williams
An Update on the Global Epidemic of Human T-Cell Lymphotrophic Virus Type-I (HTLV-I)
Journal of Long-Term Effects of Medical Implants, Vol.27, 2017, issue 2-4
Lisa G. Hill, Richard Edlich, Freddie M. Williams
Mechanisms Behind the Anti-inflammatory Actions of Insulin
Critical Reviews™ in Immunology, Vol.31, 2011, issue 4
Morley D. Hollenberg, Eric Hyun, Rithwik Ramachandran, Nathalie Vergnolle
Cholelithiasis and Cholecystitis
Journal of Long-Term Effects of Medical Implants, Vol.15, 2005, issue 3
Richard Edlich, Bruce D. Schirmer, Kathryne L. Winters